OLYSIO® sales during the first quarter 2015 Stockholm,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OLYSIO® sales during the first quarter 2015

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that the global first quarter net sales of OLYSIO® (simeprevir) amounted to 234 MUSD, of which 98 MUSD were sales in the USA. Medivir’s royalties based on sales for the first quarter are calculated from the lowest royalty tier and currency conversion from USD to Euro is based on the YTD exchange rate. The royalty amounted to 129 MSEK (13.8 MEUR). OLYSIO® global net sales Sales in MUSD Market Q1 -2015 Q1-2014 Change US 98 291 -66% RoW 136 63 116% Total global net sales MUSD 234 354 -34% Medivir will publish its Financial Statement on May 5, 2015 at 10.00 CET followed by a conference call for investors, analysts and the media at 12.30 CET. More information about the conference call/webcast will be posted at www.medivir.com. For more information please contact: Ola Burmark, CFO: +46 725 480 580 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 14 April 2015. About Simeprevir (OLYSIO®) Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen Sciences Ireland UC and Medivir AB and indicated for the treatment of chronic hepatitis C infection as a component of a combination antiviral treatment regimen. Simeprevir efficacy has been established in HCV genotype 1 and HCV genotype 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. In November 2013, simeprevir was approved by the U.S. Food & Drug Administration and, in May 2014, it was granted marketing authorisation by the European Commission. Subsequent marketing authorisations have followed in several other countries around the world. Indications vary by market. About Medivir Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 3

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 4

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Cut Winter Heating Costs with Townsend's Rebate Help

Updated Category News Views 9

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 5

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 4

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 8

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 3

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionary Imaging Techniques for Lung Cancer Treatment Success

Updated Category News Views 37

Revolutionary Techniques in Lung Cancer Management Onc.AI, a leading digital health innovator, is making strides in oncology clinical management with its pioneering approach toward imaging in advanced non-small cell lung cancer (NSCLC). The company focuses on integrating artificial intelligence into healthcare to enhance patient survival rates in cancer treatments....

Continue Reading
Kane Biotech Secures Funding Through Private Placement Initiative

Updated Category News Views 173

Kane Biotech Achieves Significant Milestone with Recent Funding Kane Biotech Inc. has recently made headlines by completing the first closing of its exciting non-brokered private placement offering. This strategic move is set to enhance the company’s capacity to innovate and expand its market presence. Private Placement Offering Details Under this newly announced...

Continue Reading
Apple Adjusts iPhone Air Production Amidst Strong Demand Shift

Updated Category News Views 183

Apple's Strategic Shift in iPhone Production Apple Inc. (NASDAQ:AAPL) has made a significant decision to decrease production orders for its iPhone Air while ramping up production for other flagship models like the iPhone 17. This change comes amid a surge in demand for these devices, particularly in markets that are seeing stronger consumer engagement. Weak Demand Impacts...

Continue Reading
Navigating Legal Proceedings: Insights for RxSight Investors

Updated Category News Views 273

A Comprehensive Guide for RxSight Investors Amid Legal Concerns Investors in RxSight, Inc. should be aware of the growing legal challenges facing the company. Robbins Geller Rudman & Dowd LLP is leading a class action lawsuit aimed at representing those who have faced significant financial losses while investing in RxSight (NASDAQ: RXST). This article delves into the...

Continue Reading
Reusable Laryngoscope System Market Growth Projections for 2034

Updated Category News Views 120

Tremendous Growth in the Reusable Laryngoscope System Market The reusable laryngoscope system market is on track for significant expansion, currently valued at around $920 million in the near term. With the healthcare industry increasingly leaning towards efficient and cost-effective solutions, this market is projected to reach approximately $1.8 billion by the year 2034....

Continue Reading